PANORAMA
| Patologia: | Miastenia Gravis |
| Area Tematica: | Ingegneria tissutale e medicina rigenerativa |
| Data di Inizio Progetto: | 01.04.2026 |
| Data di Fine Progetto: | 31.03.2028 |
| Finanziamento: | € 500.000,00 |
| Partenariato | Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico IRCCS Ospedale San Raffaele |
Irreversibile end-plate disruption might explain treatment-refractory symptoms in myasthenia gravis, characterised by autoreactive antibody-mediated block at the neuromuscular junction (NMJ). We will employ human-derived neuromuscular organoids exposed to patient serum to uncover pathogenic mechanisms responsible for NMJ damage and to identify molecular targets to enhance regeneration.